Solid Tumor Testing Market Report: Market Size & Forecast 2026

The solid tumor testing market covers a wide array of diagnostic technologies used to identify and profile cancerous solid tissues, distinguishing it from hematologic malignancies. The market encompasses immunohistochemistry (IHC), polymerase chain reaction (PCR), next-generation sequencing (NGS), and other molecular diagnostic platforms. While the broader oncology therapeutics and diagnostics sphere is valued at $431 billion in 2025, the dedicated solid tumor testing segment itself is estimated in the tens of billions, with the cancer biomarker testing component alone valued at $37.58 billion in 2025.

• •Technologies span NGS, PCR, IHC, and emerging liquid biopsy platforms
• •Cancer biomarker testing segment alone valued at $37.58 billion in 2025
• •Market serves clinical diagnostics, drug development companion testing, and research applications

Rising global cancer incidence, particularly in aging populations, is a primary catalyst as more patients require molecular profiling to guide treatment decisions. Advances in NGS and PCR technologies have dramatically reduced sequencing costs while improving accuracy, making comprehensive genomic profiling accessible in more clinical settings. The growing pipeline of targeted therapies and immunotherapies depends heavily on companion diagnostics, creating sustained demand for solid tumor testing platforms that can identify actionable mutations and biomarkers.

• •Precision oncology initiatives require routine molecular profiling of solid tumors
• •Companion diagnostics development tied directly to new targeted and immuno-oncology drugs
• •Healthcare infrastructure improvements in emerging markets expanding access to advanced diagnostics

The market is segmented by technology type, with NGS and PCR representing the fastest-growing segments due to their ability to detect multiple genetic alterations simultaneously. Segmentation by cancer type includes breast, lung, colorectal, prostate, and liver cancers, with lung and breast cancer testing holding the largest share due to high incidence rates. Geographically, North America leads the market supported by advanced healthcare infrastructure and favorable reimbursement policies, while the Asia-Pacific region is emerging as the fastest-growing market driven by rising cancer burden and expanding diagnostic capabilities.

• •NGS and PCR technologies are the dominant and fastest-growing testing platforms
• •Breast and lung cancers account for the largest testing volumes by cancer type
• •Asia-Pacific is the fastest-growing regional market due to rising healthcare investment

What are the recent trends and outlook?

The market is seeing a pronounced shift toward comprehensive genomic profiling and multi-cancer early detection tests that can screen for multiple tumor types from a single sample. Artificial intelligence and machine learning are being integrated into pathology workflows to improve diagnostic accuracy and accelerate turnaround times for complex molecular tests. With the broader solid tumor market projected to maintain a 19.7% growth trajectory, ongoing investment in R&D, consolidations among diagnostic laboratories, and evolving regulatory pathways for novel biomarkers will shape the competitive landscape through the end of the decade.

• •Multi-cancer early detection and liquid biopsy technologies gaining clinical traction
• •AI-powered pathology tools enhancing diagnostic speed and precision in solid tumor analysis
• •Regulatory streamlining for novel biomarker approvals expected to accelerate product introductions